Literature DB >> 16598648

Role of soluble interleukin-2 receptor levels in patients with latent tuberculosis.

David Shitrit1, Gabriel Izbicki, Ariella Bar-Gil Shitrit, Meir Raz, Jaquline Sulkes, Mordechai Rehven Kramer.   

Abstract

Serum soluble interleukin-2 receptor (sIL-2R) serves as a marker of disease activity in patients with tuberculosis (TB). However, little is known about its role in latent TB. The aim of this study was to assess the levels of sIL-2R in patients with latent TB and correlate them with the purified protein derivate (PPD) test results. Patients with a diagnosis of latent TB were divided into three subgroups by induration size: <10 mm, 10-20 mm, >20 mm. Blood was collected for sIL-2R assay. Findings were compared to a healthy control group. The study group consisted of 44 patients (68% male) of mean ( +/- SD) age 20 +/- 10 years, and the control group consisted of 41 subjects (42% male) aged 31 +/- 11 years. Comparison of the two groups yielded a significantly higher serum sIL-2R level in the patients (450 +/- 224 U/ml vs. 374 +/- 30 U/ml, p = 0.03). Mean sIL-2R levels were significantly correlated with the presence of latent TB (p = 0.03), and with purified protein derivative (PPD) subgroups: 387 +/- 177 U/ml for induration size <10 mm, NS; 450 +/- 238 U/ml for 10-20 mm, p = 0.04, and 605 +/- 235 U/ml for >20 mm, p < 0.0001. sIL-2R assay may serve as an additional tool to estimate the extent of the immune response in patients with latent TB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598648     DOI: 10.1007/s00408-005-2558-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   3.777


  20 in total

1.  American Thoracic Society. Diagnostic standards and classification of tuberculosis.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1990-09

2.  An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro.

Authors:  D L Nelson; L A Rubin; C C Kurman; M E Fritz; B Boutin
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

Review 3.  The immunology of mycobacterial diseases.

Authors:  D Edwards; C H Kirkpatrick
Journal:  Am Rev Respir Dis       Date:  1986-11

4.  Editorial: Delayed hypersensitivity and immunity in tuberculosis.

Authors:  M J Lefford
Journal:  Am Rev Respir Dis       Date:  1975-03

5.  The released interleukin 2 receptor binds interleukin 2 efficiently.

Authors:  L A Rubin; G Jay; D L Nelson
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

6.  Usefulness of soluble interleukin 2 receptor in differentiating tuberculous and carcinomatous pleural effusions.

Authors:  S C Chang; Y T Hsu; Y C Chen; C Y Lin
Journal:  Arch Intern Med       Date:  1994-05-23

Review 7.  Interleukin-2: inception, impact, and implications.

Authors:  K A Smith
Journal:  Science       Date:  1988-05-27       Impact factor: 47.728

8.  T lymphocyte activation in patients with active tuberculosis.

Authors:  C H Chan; K N Lai; J C Leung; C K Lai
Journal:  Am Rev Respir Dis       Date:  1991-08

9.  Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis.

Authors:  T C Y Tsao; C C Huang; W K Chiou; P Y Yang; M J Hsieh; K C Tsao
Journal:  Int J Tuberc Lung Dis       Date:  2002-08       Impact factor: 2.373

10.  Transient expression of interleukin 2 receptors. Consequences for T cell growth.

Authors:  D A Cantrell; K A Smith
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  5 in total

1.  MicroRNA-365 in macrophages regulates Mycobacterium tuberculosis-induced active pulmonary tuberculosis via interleukin-6.

Authors:  Qingzhang Song; Hui Li; Hua Shao; Chunling Li; Xiao Lu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Increased cytokines response in patients with tuberculosis complicated with chronic obstructive pulmonary disease.

Authors:  Shenjie Tang; Haiyan Cui; Lan Yao; Xiaohui Hao; Yun Shen; Lin Fan; Hua Sun; Zhanjun Zhang; Jian An Huang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

3.  Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment.

Authors:  Sasha E Larsen; Susan L Baldwin; Mark T Orr; Valerie A Reese; Tiffany Pecor; Brian Granger; Natasha Dubois Cauwelaert; Brendan K Podell; Rhea N Coler
Journal:  Vaccines (Basel)       Date:  2018-05-24

4.  Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment.

Authors:  Xuejiao Luo; Furong Wu; Jun Ma; Heping Xiao; Haiyan Cui
Journal:  J Int Med Res       Date:  2018-05-13       Impact factor: 1.671

5.  Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid.

Authors:  Eleane de Oyarzabal; Lourdes García-García; Claudia Rangel-Escareño; Leticia Ferreyra-Reyes; Lorena Orozco; María Teresa Herrera; Claudia Carranza; Eduardo Sada; Esmeralda Juárez; Alfredo Ponce-de-León; José Sifuentes-Osornio; Robert J Wilkinson; Martha Torres
Journal:  J Immunol Res       Date:  2019-12-06       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.